Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014
description
Transcript of Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014
![Page 1: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/1.jpg)
Approach to Newly Diagnosed T2DM -
Looking at ADA Statement 2014
DR SITI AISYAH ABD MAJIDFAMILY MEDICINE TRAINEE, PPUKM
![Page 2: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/2.jpg)
T2DM: Global Burden• 347 million people worldwide have diabetes .
• In 2004, an estimated 3.4 million people died from consequences of high fasting blood sugar.
• More than 80% of diabetes deaths occur in low- and middle-income countries.
• WHO projects that diabetes will be the 7th leading cause of death in 2030.
• Healthy diet, regular physical activity, maintaining a normal body weight and avoiding tobacco use can prevent or delay the onset of type 2 diabetes.
WHO (2013)
![Page 3: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/3.jpg)
![Page 4: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/4.jpg)
![Page 5: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/5.jpg)
![Page 6: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/6.jpg)
![Page 7: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/7.jpg)
![Page 8: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/8.jpg)
![Page 9: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/9.jpg)
![Page 10: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/10.jpg)
![Page 11: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/11.jpg)
![Page 12: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/12.jpg)
![Page 13: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/13.jpg)
![Page 14: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/14.jpg)
![Page 15: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/15.jpg)
![Page 16: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/16.jpg)
Risk Factors
![Page 17: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/17.jpg)
![Page 18: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/18.jpg)
American Diabetes Association (ADA) 2014: Clinical Practice Recommendations 2014
![Page 19: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/19.jpg)
Case Discussion• AH is a 43-year-old Malay man, was recently
diagnosed to have T2DM after presented with typical osmotic symptoms of polydipsia and polyuria for 6 months duration. He has comorbid conditions of hypertension, morbid obesity and tobacco use as well as strong family history of DM.
![Page 20: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/20.jpg)
Current measurements include:
BP 132/80, PR 78 bpm
BMI 42.8
HbA1C - 7.4%
Total cholesterol - 6.2 mmol/L
LDL Cholesterol – 2.8 mmol/L
HDL – 1.1 mmol/L
TG – 1.6 mmol/L
GFR>73
Urine albumin 1+
Medications are:
Perindopril 8mg daily
Metformin 1g bd
HCTZ 12.5 mg daily
Aspirin 75mg daily
![Page 21: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/21.jpg)
• He has failed to lose weight & stop smoking, but does take her medications, check her blood sugars & see the ophthalmologist. He presents for follow up diabetes care.
![Page 22: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/22.jpg)
Diagnosis• The diagnosis of diabetes requires one of the
following:
• A fasting glucose ≥ 126 mg/dL (> 7 mmol/L)
• A hemoglobin A1c level ≥ 6.5%
• A 75-gram 2-hour glucose level ≥ 200 mg/dL, or
• A random glucose level > 200 mg/dL (> 11.1
mmol/L) in a markedly symptomatic patient
![Page 23: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/23.jpg)
<7% (ADA) for prevention of microvascular disease –level A
<6.5 % (ACCE) level D- but must be formulated in context of individual patient’s life expectancy, comorbid conditions, presence or absence of micro and macrovascular complications, overall cardiovascular risk factors and risk for severe hypoglycemia.
Goal of A1C 7-8% for those with severe hypoglycemia, limited life expectancy, advanced micro or macrovascular disease, extensive comorbid conditions, long-standing disease uncontrolled despite extensive effort –Level A
Goals for Type 2 DiabeticsHbA1C
![Page 24: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/24.jpg)
![Page 25: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/25.jpg)
![Page 26: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/26.jpg)
Glucose Monitoring• Continuous glucose monitoring was added on top of
SMBG as a part of glucose monitoring.
• supplemental tool to SMBG in pts with hypoglycaemia unawareness and/or frequent hypoglycaemic episodes.
• CGM use is associated with HbA1c lowering by ~0.26%.
• ASPIRE trial – CGM reduced nocturnal hypoglycaemia without increasing HbA1c level and reduced severe hypoglycaemia for those with h/o nocturnal hypoglycaemia.
![Page 27: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/27.jpg)
• BP <140/80 with use of DASH diet-low sodium, counseling by nutritionist, level A for DASH diet, use of ACE/ARB as primary agents for reduction of BP.
• For reduction in cardiovascular events, use of ACEi, ARB, ARBs, beta blockers, diuretics & CCB is beneficial.
Blood Pressure Control
![Page 28: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/28.jpg)
LDL < 2.6 mmol/L (without overt CVD), < 1.8 mmol/L (with overt CVD).
TG < 1.7 mmol/L
HDL < 1.0 mmol/L (men), < 1.3 mmol/L (women)
Lifestyle modification – reduced saturated fat, trans fat & cholesterol intake; increase n-3 fatty acids, viscious fibre & plant sterols; wt loss, increased physical activity. Level A
Statin therapy should be added to lifestyle therapy, regardless of baseline lipid levels, for DM pts: With overt CVD
Without CVD + 40 y/o + >1 CVD risk factors
Goals for Lipids
![Page 29: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/29.jpg)
Pharmacological Therapy• Pharmacological Therapy for Hyperglycemia in
Type 2 Diabetes was changed from 3–6 months to 3 months for a trial with non-insulin monotherapy.
![Page 30: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/30.jpg)
![Page 31: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/31.jpg)
![Page 32: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/32.jpg)
Medical Nutrition Therapy• Medical Nutrition Therapy was revised to reflect the
updated position statement on nutrition therapy for adults with diabetes.
• Comprehensive group diabetes education programmes including nutrition therapy have reported HbA1c decrease by 0.5-2.0% in T2DM.
• Weight loss of 2-8kg in T2DM pt:• Increase HDL-C
• Decrease TG
• Decrease BP
![Page 33: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/33.jpg)
• Some eating pattern have been shown to be effective in managing DM eg Mediterranean style, DASH- style (Dietary Approaches to Stop HPT), vegetarian and lower-carbohydrates pattern.
• Cochrane review – decreasing Na intake reduces BP in those with DM. DM pt needs further reduction in Na intake compared to general population. Recommendation for general population <2,300mg/day.
![Page 34: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/34.jpg)
Smoking cessation• Addition of pharmacological therapy to counselling
is more effective than treatment alone.
• Recent research demonstrated that initial wt gain following smoking cessation does not diminish the substantial CVD risk benefit realized from smoking cessation.
![Page 35: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/35.jpg)
Macrovascular
• Cardiovascular disease-coronary, peripheral, carotid, cerebrovascular
Microvascular
• Nephropathy
• Retinopathy
• Neuropathy
Depression
Sleep Apnea
Evaluation for Complications
![Page 36: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/36.jpg)
CVD & Antiplatelet agents • Antiplatelet Agents was revised to recommend more
general therapy .
• Use aspirin therapy as a secondary prevention strategy in those with a h/o CVD.
• If allergy to aspirin, clopidogrel should be used.
• Dual antiplatlet therapy is reasonable for up to a year after an ACS.
• Benefit of using aspirin in primary prevention among pts with no previous CV events is more controversial, both for pts with and without a history of DM.
![Page 37: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/37.jpg)
Nephropathy• Nephropathy was revised to
remove terms “microalbuminuria” and “macroalbuminuria,” which were replaced with:
• “albuminuria 30–299 mg/24 h” (previously microalbuminuria), and;
• “albuminuria ≥300 mg/24 h” (previously macroalbuminuria).
![Page 38: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/38.jpg)
• Optimize glucose & BP control to reduce risk or slow the progression of nephropathy.
• Annual test to quantify urine albumin excretion in T2DM should be performed starting at Dx.
• Measurement of eGFR from serum creatinine.
![Page 39: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/39.jpg)
![Page 40: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/40.jpg)
![Page 41: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/41.jpg)
Retinopathy• Retinopathy was revised to recommend exams
every 2 years versus 2–3 years, if no retinopathy is present.
• If retinopathy is present, subsequent examination should be repeated annually by ophthalmologist or optometrist.
• Optimize glucose & BP control to reduce risk or slow the progression of nephropathy.
![Page 42: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/42.jpg)
![Page 43: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/43.jpg)
Neuropathy• Neuropathy was revised to provide more
descriptive treatment options for neuropathic pain.
• May present as distal symmetric polyneuropathy (DSN), diabetic autonomic neuropathy (DAN), cardiovascular autonomic neuropathy (CAN), GI neuropathy & genitourinary tract neuropathy.
![Page 44: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/44.jpg)
• Glycemic control – tight & stable.
• An intensive CV risk intervention (glucose, BP, lipids, smoking, lifestyle) has been shown to reduce the progression & development of CAN among pt with T2DM.
• Use of metoclopramide (Maxolon®) in presence of gastroparesis Sx to be reserved to only severe cases that are unresponsive to other therapies. Extrapyramidal effects should be monitored.
• ED – PDE type 5 inhibitors, intracorporeal or intraurethral prostaglandin, vacuum devices or penile prostheses. However, they do not change natural history of disease process, but improve pt’s QOL.
![Page 45: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/45.jpg)
![Page 46: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/46.jpg)
Hospital Care• Diabetes Care in the Hospital was updated to
discourage the sole use of sliding scale insulin in non-critically ill patient.
![Page 47: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/47.jpg)
![Page 48: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/48.jpg)
Foot Care
![Page 49: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/49.jpg)
• Increased risk of foot ulcers & amputation is seen in:• Previuos h/o amputation
• Past foot ulcer hx
• Peripheral neuropathy
• Foot deformity eg hammertoes, prominent metatarsal head, bunions, Charcot joint
• Peripheral vascular disease
• Diabetic nephropathy esp on dialysis
• Poor glycemic control
• Cigarette smoking
![Page 50: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/50.jpg)
![Page 51: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/51.jpg)
Other Common Comorbid Conditions
COMORBIDITIES NOTES
Depression Highly prevalent in DM and has worse outcome. Assessment is recommended in DM (geriatric depression scale, DASS).
OSA Prevalence DM with OSA is 23%. Rx significantly improves QOL and BP control.
Fatty liver Intervention that improve metabolic abnormalities are beneficial.
![Page 52: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/52.jpg)
COMORBIDITIES NOTES
Cancer T2DM increased risk of cancer (liver, pancreas, endometrium, colon, breast & bladder). Cancer screening and reduction in modifiable cancer risk factors (obesity, smoking, physical inactivity) are encouraged.
Fractures BMD test is recommended. Avoid thiazolidinediones.
Cognitive Impairment Increased risk of dementia.
Periodontal assessment Periodontal disease is more severe in DM pt. Referral to dentist is beneficial.
Hearing impairment NHANES analysis – 2x risk in diabetics compared to non-diabetics.
![Page 53: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/53.jpg)
T2DM: Summary of Revisions to the ADA 2014 Clinical Practice
Recommendations • Diagnosis of Diabetes was clarified to note that A1C is one of
three available methods to diagnose diabetes.
• Glucose Monitoring was revised to add additional continuous glucose monitoring language, reflecting the recent approval of a sensor-augmented low glucose suspend threshold pump for those with frequent nocturnal hypoglycemia and/or hypoglycemia unawareness.
• Pharmacological Therapy for Hyperglycemia in Type 2 Diabetes was changed from 3–6 months to 3 months for a trial with noninsulin monotherapy.
• Medical Nutrition Therapy was revised to reflect the updated position statement on nutrition therapy for adults with diabetes.
![Page 54: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/54.jpg)
• Antiplatelet Agents was revised to recommend more general therapy (i.e., dual antiplatelet therapy versus combination therapy with aspirin and clopidogrel).
• Nephropathy was revised to remove terms “microalbuminuria” and “macroalbuminuria,” which were replaced with albuminuria 30–299 mg/24 h (previously microalbuminuria) and albuminuria ≥300 mg/24 h (previously macroalbuminuria).
• Retinopathy was revised to recommend exams every 2 years versus 2–3 years, if no retinopathy is present.
• Neuropathy was revised to provide more descriptive treatment options for neuropathic pain.
• Diabetes Care in the Hospital was updated to discourage the sole use of sliding scale insulin in the inpatient hospital setting.
![Page 55: Approach to Newly Diagnosed T2DM - Looking at ADA Statement 2014](https://reader036.fdocuments.us/reader036/viewer/2022062811/56815ecd550346895dcd542c/html5/thumbnails/55.jpg)
THANK YOU